Table 1.
Combined flow-cytometric and immunofluorescence analysis of co-expression of CD176 with CD44 or CD133 on cancer cell lines (per cent of cells belonging to the respective group)
| Tissue derivation | Cell lines | CD44−/CD176− (%) | CD44−/CD176+ (%) | CD44+/CD176− (%) | CD44+/CD176+ (%) | CD133−/CD176− (%) | CD133−/CD176+ (%) | CD133+/CD176− (%) | CD133+/CD176+ (%) |
|---|---|---|---|---|---|---|---|---|---|
| Lung cancer | |||||||||
| Adenocarcinoma | SPC-A-1 | ∼6 | ∼20 | ∼5 | >60 | ∼11 | >60 | <1 | <1 |
| Adenocarcinoma | GLC-82 | <1 | ∼4 | ∼1 | >60 | ∼7 | >60 | <1 | <1 |
| Small cell carcinoma | NCIH446 | ∼10 | ∼8 | ∼17 | >60 | ∼15 | >60 | <1 | <1 |
| Giant cell carcinoma | 801-D | ∼23 | ∼6 | ∼46 | ∼23 | ∼60 | ∼25 | ∼11 | ∼4 |
| Breast cancer | |||||||||
| Adenocarcinoma | MDA-231 | >60 | ∼2 | ∼43 | ∼1 | >60 | ∼3 | <1 | <1 |
| Adenocarcinoma | MDA-435 | >60 | 16 | ∼10 | ∼4 | >60 | ∼20 | <1 | <1 |
| Adenocarcinoma | MCF-7 | >60 | ∼4 | ∼24 | ∼7 | >60 | ∼11 | <1 | <1 |
| Liver cancer | |||||||||
| HCC | HepG-2 | ∼6 | ∼17 | ∼23 | ∼54 | ∼29 | >60 | <1 | <1 |
| HCC | HuH-7 | >60 | ∼13 | <1 | <1 | >60 | ∼13 | ∼2 | ∼4 |
HCC, hepatocellular carcinoma.